Showing results (21-30 of 29) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2006
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumorsMihaela Ginj, Hanwen Zhang, Beatrice Waser, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 2, 2006
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targetingDamian Wild, Martin Béhé, Andreas Wicki, et al.Bioconjugate Chemistry|May 16, 2002
NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumorsKlaus-Peter Eisenwiener, M I M Prata, I Buschmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersAnna Imhof, Philippe Brunner, Nicolas Marincek, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 26, 2003
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometalsDamian Wild, Jörg S Schmitt, Mihaela Ginj, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2005
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomasMarcus Henze, Antonia Dimitrakopoulou-Strauss, Stefanie Milker-Zabel, et al.Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomasLisa Bodei, Daria Handkiewicz-Junak, Chiara Grana, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinomaAndreas Wicki, Damian Wild, Daniel Storch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancersLinda Villard, Anna Romer, Nicolas Marincek, et al.Pageof 3